Please login to the form below

19

Revenue 2017

Celgene

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... Vidaza was a big seller for Celgene in the past but has been hit by generic

AbbVie/Allergan's merger faces public opposition

Potential push-back from the FTC could create problems however, especially in light of the regulatory difficulties experienced by Bristol-Myers Squibb in its $73bn takeover of Celgene.

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Also coming through the pipeline is Biogen’s Tecfidera follow-up diroximel fumarate (BIIB098), Novartis’ new antibody ofatumumab, and Celgene’s S1P receptor modulator ozanimod that is due for regulatory decision

Third strike for BMS’ Opdivo in brain cancer

However, a few other candidates such as Tocagen’s gene therapy Toca511/Toca FC and Celgene’s proteasome inhibitor marizomib are due to generate results in the next couple of years.

Celgene boosts IO presence with Immatics deal

Celgene will also be able to manufacture and gain worldwide commercialisation rights to the TCR-T cell therapies developed by Immatics. ... Celgene is preparing to file both these lead candidates before the end of 2020.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology